These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 30403305)

  • 21. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
    Dong H; Wang X; Dong Y; Lei J; Li H; You H; Wang M; Xing J; Sun J; Zhu H
    Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Macrolides: pharmacokinetics and pharmacodynamics.
    Van Bambeke F; Tulkens PM
    Int J Antimicrob Agents; 2001; 18 Suppl 1():S17-23. PubMed ID: 11574190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults.
    Kispal B; Walker SAN
    Eur J Clin Pharmacol; 2021 Feb; 77(2):197-205. PubMed ID: 32975650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
    Reed MD
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides.
    Deziel-Evans LM; Murphy JE; Job ML
    Clin Pharm; 1986 Apr; 5(4):319-24. PubMed ID: 3709080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.
    Slavik RS; Jewesson PJ
    Clin Pharmacokinet; 2003; 42(9):793-817. PubMed ID: 12882587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients.
    Ruiz J; Ramirez P; Company MJ; Gordon M; Villarreal E; Concha P; Aroca M; Frasquet J; Remedios-Marqués M; Castellanos-Ortega Á
    J Glob Antimicrob Resist; 2018 Mar; 12():90-95. PubMed ID: 29017888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibiotic pharmacokinetic and pharmacodynamic parameters in pediatric clinical practice.
    Cohen R; Grimprel E
    Arch Pediatr; 2017 Dec; 24(12S):S6-S8. PubMed ID: 29290237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
    Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective.
    Pea F; Poz D; Viale P; Pavan F; Furlanut M
    J Antimicrob Chemother; 2006 Aug; 58(2):380-6. PubMed ID: 16735422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.
    Imberti R; Cusato M; Villani P; Carnevale L; Iotti GA; Langer M; Regazzi M
    Chest; 2010 Dec; 138(6):1333-9. PubMed ID: 20558557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does the dose matter?
    Craig WA
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S233-7. PubMed ID: 11524724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and Pharmacodynamics of Temocillin.
    Alexandre K; Fantin B
    Clin Pharmacokinet; 2018 Mar; 57(3):287-296. PubMed ID: 28849402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential impact of quantitative susceptibility tests on the design of aminoglycoside dosing regimens.
    McCormack JP; Schentag JJ
    Drug Intell Clin Pharm; 1987 Feb; 21(2):187-92. PubMed ID: 3829911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics.
    Toutain PL; del Castillo JR; Bousquet-Mélou A
    Res Vet Sci; 2002 Oct; 73(2):105-14. PubMed ID: 12204627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.
    Jacobs MR
    Clin Microbiol Infect; 2001 Nov; 7(11):589-96. PubMed ID: 11737083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.